TDF and LdT in Immune-tolerant CHB Patients Awaiting Assisted Reproduction

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2015
Immune-tolerant patients with chronic hepatitis B (CHB) awaiting assisted reproduction (AR) are required to initiate antiviral therapy due to laboratory safety. Additionally, rapid virus elimination is suggested to faciliate timely performance of AR. However, no consensus is reached regarding the antiviral therapy in this group. This study aimed to explore the efficacy and safety of tenofovir (TDF) and telbivudine (LdT) in this population.
Epistemonikos ID: 92322009f971b58b952cfcb75b1f0b550bb182fc
First added on: Nov 24, 2021